Biogen Inc logo

Biogen Inc

NAS:BIIB (USA)  
51
6
$ 255.02 -2.66 (-1.03%) 04:00 PM EST
P/E:
13.88
P/B:
2.55
Market Cap:
$ 36.93B
Enterprise V:
$ 37.83B
Volume:
737.10K
Avg Vol (2M):
939.36K
Also Trade In:
Volume:
737.10K
Market Cap $:
36.93B
PE Ratio:
13.88
Avg Vol (2M):
939.36K
Enterprise Value $:
37.83B
PB Ratio:
2.55

Business Description

Description
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Financials (Next Earnings Date:2023-10-25 Est.)

BIIB's 30-Y Financials
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:BIIB

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014

Biogen Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 9,971.5
EPS (TTM) ($) 18.37
Beta 0.04
Volatility % 42.11
14-Day RSI 41.32
14-Day ATR ($) 4.187527
20-Day SMA ($) 261.188
12-1 Month Momentum % 31.08
52-Week Range ($) 194.45 - 319.76
Shares Outstanding (Mil) 144.82

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Biogen Inc Filings

Filing Date Document Date Form
No Filing Data

Biogen Inc Stock Events

Event Date Price($)
No Event Data

Biogen Inc Frequently Asked Questions

What is Biogen Inc(BIIB)'s stock price today?
The current price of BIIB is $255.02. The 52 week high of BIIB is $319.76 and 52 week low is $194.45.
When is next earnings date of Biogen Inc(BIIB)?
The next earnings date of Biogen Inc(BIIB) is 2023-10-25 Est..
Does Biogen Inc(BIIB) pay dividends? If so, how much?
Biogen Inc(BIIB) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1